$288.50
-4.85
(-1.65%)
As of Sep 5, 2026, 9:15 AM EDT
Price history
Charles River Laboratories (CRL) is trading down at $288.50 (-1.65%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.
About Charles River Laboratories
Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices. Its operations span at least 20 countries, offering research models, safety assessment, and manufacturing support services to pharmaceutical, biotechnology, and government clients.
Recent News (14)
-
Is Wall Street Bullish or Bearish on Charles River Laboratories Stock?
Is Wall Street Bullish or Bearish on Charles River Laboratories Stock?
-
How an Insider CEO Is Taking a Fresh Look at Charles River
How an Insider CEO Is Taking a Fresh Look at Charles River
-
Charles River Laboratories (CRL) Q2 2026 Earnings Call Transcript
Charles River Laboratories (CRL) Q2 2026 Earnings Call Transcript
-
Charles River Associates Q2 Earnings Call Highlights Charles River Associates Q2 Earnings Call Highlights
-
Earnings call transcript: Charles River Associates tops Q2 2026 forecasts
Earnings call transcript: Charles River Associates tops Q2 2026 forecasts
-
Charles River Laboratories International Q2 Earnings Call Highlights Charles River Laboratories International Q2 Earnings Call Highlights
-
JPMorgan upgrades Charles River Labs stock rating on bookings
JPMorgan upgrades Charles River Labs stock rating on bookings
-
Charles River Laboratories International, Inc. Q2 2026 Earnings Call Summary Charles River Laboratories International, Inc. Q2 2026 Earnings Call Summary
-
Evercore ISI raises Charles River Labs stock price target on revenue growth
Evercore ISI raises Charles River Labs stock price target on revenue growth
-
Charles River Laboratories stock hits 52-week high at $266.00
Charles River Laboratories stock hits 52-week high at $266.00
-
Charles River Laboratories earnings beat by $0.28, revenue topped estimates
Charles River Laboratories earnings beat by $0.28, revenue topped estimates
-
Saol Therapeutics Announces the Acceptance of Resubmission of SL1009 (DCA) by the FDA with PDUFA Date of Dec. 30, 2026 FDA confirmed the resubmission is a complete, Class II response to the Aug. 27, 2025 CRL. Saol remains committed to working with FDA toward approval of this treatment for PDCD, a rare, life-threatenin…
-
Charles River Laboratories Earnings Preview: What to Expect Charles River Laboratories Earnings Preview: What to Expect
-
CLSA downgrades Charles River Labs stock rating on valuation
CLSA downgrades Charles River Labs stock rating on valuation
More Health Care stocks
- A Agilent Technologies
- DHR Danaher Corporation
- IQV IQVIA
- MTD Mettler Toledo
- TECH Bio-Techne
- TMO Thermo Fisher Scientific
- WAT Waters Corporation
- ABBV AbbVie